Quince Therapeutics disclosed top‑line results from its pivotal Neat Phase III trial of eDSP (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) for ataxia‑telangiectasia (A‑T) that failed to meet its primary endpoint, prompting the company to halt development and triggering a dramatic share collapse. The Neat trial did not show a statistically significant improvement on the modified International Cooperative Ataxia Rating Scale versus placebo, and secondary endpoints did not redeem the program. Analysts and company statements indicate the failure removes the lead value driver and will force strategic reassessment for the Bay Area biotech.